GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longevity Biomedical Inc (NAS:LBIO) » Definitions » Gross Profit

Longevity Biomedical (Longevity Biomedical) Gross Profit : $0.00 Mil (TTM As of . 20)


View and export this data going back to 2050. Start your Free Trial

What is Longevity Biomedical Gross Profit?

Longevity Biomedical's gross profit for the six months ended in . 20 was $0.00 Mil. Longevity Biomedical's gross profit for the trailing twelve months (TTM) ended in . 20 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Longevity Biomedical's gross profit for the six months ended in . 20 was $0.00 Mil. Longevity Biomedical's Revenue for the six months ended in . 20 was $0.00 Mil. Therefore, Longevity Biomedical's Gross Margin % for the quarter that ended in . 20 was N/A%.

Longevity Biomedical had a gross margin of N/A% for the quarter that ended in . 20 => No sustainable competitive advantage


Longevity Biomedical Gross Profit Historical Data

The historical data trend for Longevity Biomedical's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longevity Biomedical Gross Profit Chart

Longevity Biomedical Annual Data
Trend
Gross Profit

Longevity Biomedical Semi-Annual Data
Gross Profit

Competitive Comparison of Longevity Biomedical's Gross Profit

For the Biotechnology subindustry, Longevity Biomedical's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longevity Biomedical's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's Gross Profit distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's Gross Profit falls into.



Longevity Biomedical Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Longevity Biomedical's Gross Profit for the fiscal year that ended in . 20 is calculated as

Gross Profit (A: . 20 )=Revenue - Cost of Goods Sold
= -
=0.00

Longevity Biomedical's Gross Profit for the quarter that ended in . 20 is calculated as

Gross Profit (Q: . 20 )=Revenue - Cost of Goods Sold
= -
=0.00

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Gross Profit for the trailing twelve months (TTM) ended in . 20 was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Longevity Biomedical's Gross Margin % for the quarter that ended in . 20 is calculated as

Gross Margin % (Q: . 20 )=Gross Profit (Q: . 20 ) / Revenue (Q: . 20 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 /
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Longevity Biomedical  (NAS:LBIO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Longevity Biomedical had a gross margin of N/A% for the quarter that ended in . 20 => No sustainable competitive advantage


Longevity Biomedical Gross Profit Related Terms

Thank you for viewing the detailed overview of Longevity Biomedical's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Longevity Biomedical (Longevity Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.

Longevity Biomedical (Longevity Biomedical) Headlines

No Headlines